PDL BioPharma, Inc. Notes Receivable, Fair Value Disclosure
PDL BioPharma, Inc. had Notes Receivable, Fair Value Disclosure of $700.00 thousand as of 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Financial Instruments, Financial Assets, Balance Sheet Groupings
us-gaap:NotesReceivableFairValueDisclosure · last filed 2021-03-29
- 2020-12-31: Notes Receivable, Fair Value Disclosure $700.00K.
- 2019-12-31: Notes Receivable, Fair Value Disclosure $57.30M.
- 2018-12-31: Notes Receivable, Fair Value Disclosure $70.00M.
- 2018-09-30: Notes Receivable, Fair Value Disclosure $80.80M.
| Period end | Notes Receivable, Fair Value Disclosure |
|---|---|
| 2020-12-31 | $700.00K 10-K · filed 2021-03-29 |
| 2019-12-31 | $57.30M 10-K · filed 2021-03-29 |
| 2018-12-31 | $70.00M 8-K · filed 2020-06-29 |
| 2018-09-30 | $80.80M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $77.90M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $72.70M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $71.30M 10-K · filed 2019-03-15 |
| 2017-09-30 | $53.50M 10-Q · filed 2017-11-13 |
| 2017-06-30 | $52.50M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $96.50M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $107.40M 10-K · filed 2018-03-16 |
| 2015-12-31 | $109.20M 10-K · filed 2017-03-01 |
| 2012-06-30 | $7.45M 10-Q · filed 2012-08-02 |
| 2012-03-31 | $7.43M 10-Q · filed 2012-05-03 |
| 2011-12-31 | $0.00 10-Q · filed 2012-08-02 |